A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)
Trial details
- Registry ID
- NCT06868628
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase 2a Study of Foralumab Nasal in Patients With Multiple System Atrophy (MSA)NCT06868628 | TLSA | Phase 2 | Recruiting | 2027-04-01Estimated |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal ForalumabNCT07688239 | TLSA | Phase 2 | Enrolling by invitation | 2027-07Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |